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Combined heart and lung transplantation has evolved 
into a therapeutic option for patients with end-stage 
cardiopulmonary disease. Historically, Demikhov, Nep- 
tune, Webb, and Lower independently embarked on 
research that would ultimately lead to heart-lung trans- 
plantation in humans.’-4 During 1940 to 1960, these 
researchers conducted canine experiments in en-bloc 
homograft replacement of the heart and both lungs. 
Clinical attempts were delayed in the past because of 
the finding that in canines the resultant denervation of 
the lungs during these experiments destroyed the Hering- 
Bruer reflex. This resulted in a progressive decline in 
respiratory drive. Primates, however, were found to 
maintain a viable respiratory pattern.” Successful long- 
term survival in primates after experimental heart-lung 
transplantation led to the hope that this procedure 
would be successful in humans.6 
On August 31, 1968, Cooley performed the first 
heart-lung transplantation on a 2-month-old patient 
with a complete atrioventricular canal and pulmonary 
hypertension.’ The infant was weaned from cardiopul- 
monary bypass but survived only 14 hours. Further 
efforts at  heart-lung transplantation by Lillehei in 
1963* and Barnard in 19719 also failed to produce 
long-term survivors. It was not until March 8, 1981, 
that Bruce Reitz and his colleagues at Stanford Univer- 
sity performed their landmark operation that resulted 
in the first long-term survivor after heart-lung transplan- 
tation.’O We visited Stanford that same week and soon 
embarked on a similar course. 
Currently there are 122 transplant centers that list 
themselves as performing heart-lung transplantation. 
Although 2,428 such transplants have been performed 
between 1982 and 1998,l’ the number of transplants 
performed yearly peaked in 1989 at 241 transplants 
and has been declining steadily, with 151 heart-lung 
transplants being performed in 1997. Indications for 
heart-lung transplant according to the International 
Society of Heart-Lung Transplantation (ISHLT) regis- 
try include congenital heart disease (28%), primary 
pulmonary hypertension (26%), cystic fibrosis (16%), 
emphysema (4%), retransplantation (3%), idiopathic 
pulmonary fibrosis (3%), a-1 antitrypsin deficiency 
(2%), and miscellaneous (19%).” Recently there has 
been an increasing use of single and double-lung 
procedures and an awareness that most with even 
significant right-heart failure can recover without heart 
and lung transplantation. Now those with complex and 
unrorrectable congenital heart disease dominate tht. 
indication. 
Many of the pulmonary diseases such as cystic. 
fibrosis and emphysema that had previously been 
managed with combined heart-lung transplants are now 
being managed with isolated single or double-lung 
transplants. Current indications for combined heart- 
lung transplants are primarily complex congenital car- 
diopulmonary disorders with Eisenmenger’s syndrome 
and primary pulmonary disorders with severe cor 
pulrnonnle. Occasionally a patient with severe obstruc- 
tive or interstitial lung disease will qualify for heart and 
lung replacement based on poor left-heart function or 
co-existing premature coronary artery disease. 
An interesting additional application of heart-lung 
transplantation is a domino procedure. This procedure 
involves implanting a heart-lung bloc into a patient with 
end-stage lung disease whose explanted normal heart is 
then given to an isolated heart transplant candidate. 
This technique is primarily performed in centers that 
advocate heart-lung transplantation as opposed to 
double-lung transplantation for cystic fibrosis. Some 
suggest that a heart with moderate right ventricular 
hypertrophy as a response to pulmonary hypertension 
is ideal for a heart recipient with an increased transpul- 
monary pressure gradient. Those candidates with “pal- 
liated” congenital disease and with deep cyanosis and 
cardiac cirrhosis represent very challenging surgeries. 
Results reported by Yacoub et al,” in 27 cystic fibrosis 
patients showed an actuarial survival of 78% at 1 year 
and 72% at 2 years after heart-lung transplantation. 
The actuarial survival of the domino heart recipients 
was 75% at 1 year.” Oaks et al,13 reported the experi- 
ence at Papworth Hospital (UK) from 1988 to 1992 in 
which 86 patients received a heart-lung transplant and 
32 patients received a domino heart transplant. They 
found no difference in 3-month (84% vs 83%) or 1-year 
(74% vs 76%) survival between domino and nondomino 
heart recipients. 
In the United States, the allocation of donor organs 
makes the “domino” a rare event. As of January 20, 
1999, the United Network for Organ Sharing (UNOS) 
policy 3.7 requires that candidates for heart-lung trans- 
plantation be listed separately on both heart and lung 
waiting lists. Candidates who become eligible for a heart 
transplant based on cardiac status and waiting time are 
automatically offered the combined heart-lung bloc. 
Similarly, a patient who become eligible as a lung 
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transl,Iant candidate will be offered the heart-lung f)Ioc 
if thvre are no current status-1 4 isolated heart can&- 
date- in their local regional organ prot.urement organi- 
zation. Although there still are no medical status 
criteria for prioritizing heart-lung transplant recipi- 
ent*. Ilrosperts are improved for those who are waiting. 
Tlie evaluation of a potential heart-lung hlor inrlucles 
both 1)reoperative and intraoperative assessment. The 
donor should have a normal chest radiograph, electro- 
cart liogram, and echocarcliogram and should he on 
minimal vasopressor or inotropic support. Bronchos- 
coli? and sputum analysis should be normal. The heart 
antl lungs should appear normal b y  visual inspection 
antl palpation. If any of these criteria are not met, 
comhined heart-lung donation should not be consid- 
ered. Unfortunately, less than 20% of potential heart 
donors have lungs that are suitable for a combined 
heart-lung transplant. This results in a relative short- 
age of heart-lung 1,locs. 
The operative strategy for heart-lung transplantation 
must arromplish two primary goals: ( 1) the preserva- 
tion of phrenir . recurrent laryngeal and vagus nerves 
during removal of the reripient’s native organs; and (2) 
metirulous hemostasis. Preservation of the nerves is 
often more ttifficidt than in isolated heart or lung removal 
because of the extensive mrcliastiiial dissertion required 
in heart-lung transplantation, but failure to do so 
results in profound postoperative respiratory insuffi- 
ciency, vocal cord paralysis, or gastrointestinal dysfunc- 
tion. Failure to achieve hemostasis before discontinua- 
tion of cardiopulmonary bypass often results in massive 
transfusion requirements that, in turn, endanger the 
function of the donor lungs. These particular strategies 
will be highlighted in SURGICAL TECHNIQUE. 
SURGICAL TECHNIQK’E 
Currently our preferred method of heart-lung preserva- 
tion involves the use of cold intracellular electrolyte- 
based pulmonary artery flush and standard cardiople- 
@a. Concerns about unreliable pulmonary function after 
transplantation have led to a series of different types of 
solutions and procedures to preserve the lungs. I n  the 
past we have used normothermic autoperfusion, hypo- 
thermic cardiopulmonary perfusion, University of Wis- 
consin solution, and a broad array of various perfusate 
“cocktails” designed to reduce reperfusion injury. For 
many reasons, not the least of which include cost, we 
currently use a pulmoplegia solution composed of basic 
Euro-Collins solution (Fresenius USA, Ogden, UT) with 
500 pg of prostaglandin E-1 and 50 mg of nitroglycerin. 
The well known potassium-related vasoconstrictive ef- 
fect of this intracellular electrolyte composition is amelio- 
rated by pretreatment with additional intravenous prosta- 
glandins delivered into the pulmonary artery before infusion 
of pulmoplegia. We also routinely employ retrograde 
perfusion of pulmonary veins. This enhances the adequacy 
of the regional distribution of coolant and assists in the 
removal of acute pulmonary emboli and thrombi. - 
1 See legend on opposite page. 
1 Procurement of heart-lwig bloc. After diagnostic bronchoscopy and instillation of aerosolized 
antibiotics, the tlonor operation begins with an extension of the abdominal mid-line incision and a 
median sternotoiny. The anterior pleura are opened and both the right and left lungs are inspected 
for evidencp of contusion, atelectasis, and/or consolidation. The heart is also inspected for its 
contractility and the coronary arteries are palpated to exclude gross calcification. The anterior 
pericardium is trimmecl to the hilum bilaterally, and perfusion cannulae are placed in the ascending 
aorta and main pulmonary artery. When the abdominal organs have been prepared for removal by 
others, 500 pg of prostaglandin E-1 is infused through the pulmonary artery cannula. Once 
prostaglandin El-associated systemic arterial hypotension is noted, the ascending aorta is 
crossclamped just proximal to the innominate artery. The abdominal team begins to flush their 
organs of interest, while the cardiopulmonary surgeons begin to remove the heart-lung bloc as 
follows. The superior vena cava is stapled with a vascular stapler placed at the junction of the 
innominate and right internal jugular veins. The inferior vena cava is divided at the diaphragm. It  is 
important to discuss the needs of the liver retrieval team because an ample stump of inferior cava is 
generally more critical for implantation of the liver than the heart. One liter of cold crystalloid 
cardioplegia with 50 mg of nitroglycerin added is instilled into the aortic root. During the infusion of 
cardioplegia, the tip of the left atrium is amputated to ensure adequate decompression of the left 
ventricle and pulmonary veins. The pulmoplegia is then begun. The pulmonary perfusion is given 
from an elevated bag and continued for a total dose of 100 mL/kg, while the lungs are gently 
ventilated. The flow of pulmoplegia is directed equally into the left and right main pulmonary artery 
by gentle rotation of the cannula. Equal distribution is verified by symmetric blanching of the lungs, 
and overpressurization of the pulmonary artery is assured by finger palpation. At the completion of 
the cardioplegia, the aorta is transsected to provide further outlet for the high volume pulmonary 
flush. Extraction is begun at a careful place that permits accuracy and limits missteps. Both inferior 
left and right pulmonary ligaments are divided. The middle aspect of the posterior mediastinurn 
becomes the next focus, and the pericardium abutting the diaphragm is divided. It is then grasped 
along the anterior hilum with forceps, and reflected superioanteriorly. 
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2-3 This provides tension along the posterior mediastinum ancl 
allows exposure for precise incisions. Care is taken to avoid entering 
the esophagus as this dissection is continued to the carina. 
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4 It is important that bronchial arteries are securely closed with 
hemoclips because we have found that cautery is unreliable. On the left, 
care is taken to leave a sizeable button of aortic tissue in the region of the 
ligamentum arteriosum in order to avoid inadvertently entering the 
pulmonary artery at  its bifurcation. The innominate artery is divided at 
this time, allowing easy access to the upper aspect of the middle trachea. 
The endotracheal tube is now withdrawn into the upper regions of the 
trachea, and the lungs are held partially inflated with 100% oxygen. The 
trachea is then divided with the use of a TA-55 (US Surgical Corp, 
Norwalk, CT) stapling device with a 4.8-mm staple load. 
5 The remaining loose attachments are divided, and the heart-lung bloc ran now be removed. 
The organs are then placed in a doubly wrapped plastic bag containing cold Plasma-Lyte 
solution (Baxter Healthcare Corp, Deerfield, IL) and are stored in an ice-packed cooler for 
transport. 
Implant technique. Generally we tuck the recipient’s arms at  their sides unless they are large, 
which would limit the extension of the anterior incision into the mid-posterior axilla. In this 
scenario, we elevate the arms and secure them to an ether screen above the patient. Anesthetic 
considerations include adequate cardiac and hernodynamic monitoring. We routinely place 
arterial and pulmonary artery catheters in all patients. Transesophageal echocardiography is 
used to monitor cardiac function. It is our preference to use a double-lumen endotracheal tube, 
permitting us to selectively ventilate the left and right lung for better exposure. Also, isolated 
lung ventilation allows us to retract the unventilated lung to view the posterior aspect of the 
anastomosis and inspect for integrity and bleeding. We administer Aprotinin (Bayer Corp, West 
Haven, CT) before commencement of the surgical procedure and throughout the case. Aprotinin 
has improved our ability to obtain adequate hemostasis, especially in patients with hepatic 
congestion and those with abundant pleural pulmonary adhesions, in whom postimplant 
coagulopathy is common. 
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6 Although initially we were most comfortable performing a sternotomy for all heart-lung transplant 
procedures, we now perform a bilateral intercostal transsternal incision through the fourth intercostal 
space. After opening the recipient’s chest, a pericardiotomy and bilateral pleurotomies are performed. The 
thoracic cavity is inspected for extensive adhesions that might preclude the likelihood of a successful 
operation without postoperative exsanguination. The removal of the recipient’s diseased heart and lungs 
poses the greatest technical challenge of the operative procedure. Cardiopulmonary evisceration must be 
accomplished without causing injury to the phrenic, recurrent laryngeal, and vagus nerves and demands 
fastidious attention to the hemostatic control of enlarged bronchial and mediastinal collateral vessels. It is 
preferable to excise the recipient’s heart and lungs separately. Although it is possible to remove the organs en 
bloc, exposure is improved when the ventricles and left atrium are removed first. 
Generally, not much dissection is undertaken before we initiate cardiopulmonary bypass. Recipients are 
cannulated at  the base of the innominate artery for arterial return, and venous drainage is drawn from 
bicaval cannulation sites. The cavae are then snared to provide complete cardiopulmonary bypass. The 
ascending aorta is occluded just below the aortic perfusion cannula. We choose to divide the right pulmonary 
artery and all pulmonary veins at their reflections of the pericardium. We avoid dissecting around the left 
pulmonary artery to reduce the risk of injuring the recurrent laryngeal nerve. The left atrium is then 
removed from the right atrium, and the entire interatrial septum is left intact. The pericardial well now 
contains only a right atrial cuff and a short portion of left pulmonary artery. The lungs are mobilized b y  
taking down any pleural adhesions and dividing the pulmonary ligaments. The hilar structures are isolated, 
and the pulmonary arteries and veins are divided. Specid attention must be paid to the anatomical course of the 
phrenic nerves to avoid iatrogenic injury. The right phrenic nerve is particularly at risk because it courses quite 
close to the Mum. Care also is taken to avoid h j w y  to the va@ that can be divided, if not separated, from their 
attachments to the posterior hilar structures. 
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7 Once the lungs are tethered only by their respective main bronchi, traction is used to facilitate 
circumferential dissection of the more proximal airways. Ligature or clip best controls the bronchial vessels 
encountered at this level of dissection because cautery is ineffective or, at best, provides only temporary 
control. The mainstem bronchi are stapled closed, and the lungs are amputated. Meticulous hemostasis of 
the posterior mediastinum and peribronchial areas must be completed at  this juncture in the operation 
because these regions will be inaccessible after implantation of the donor organs. It is preferable to avoid any 
unnecessary dissection of the posterior and mid-mediastinal structures that are not intimately vested in the 
lungs and airways. Our choice to avoid a tracheal anastomoses in difference to a bronchial one has evolved 
from lessons learned about the hazards of bleeding from the mediastinum. 
The donor heart-lung bloc is removed from cold storage and prepared for placement into the recipient. 
The stapled trachea and proximal mainstem airways are excised so that the anastomoses can proceed at  two 
cartilaginous rings above the left and right upper-lobe origins. The divided bronchi are marked with 
temporary sutures to help localize them when passed into their respective orifices. Intrabronchial cultures 
are taken from the left and right lung. The donor organs are examined and anatomically oriented so that 
they may be positioned appropriately within the recipient. In anticipation of placing the donor lungs in their 
respective thoraces, the phrenic nerves are isolated on pericardial pedicles. 
8 Accordingly, incisions are extended cephalad and caudad within the lumens of 
the transsected pulmonary veins (A-B). These openings enable the pericardial pedicle 
to be reflected anteriorly. They must he large enough to permit the partially inflated 
lungs of the donor to pass through. The left lung and heart are slipped into the left 
chest through the associated pericardial window. 
8 (continued) 
9 The larger right lung is then carefully passed behind the atrial cuff when present or directly through the 
right-sided pericardial window. With the right lung in the pericardial space, the heart is then drawn back from the 
left chest to lie within the pericardium. 
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10 As discussed, perhaps somewhat uniquely, we have evolved from a distal 
tracheal anastomosis to one that uses a bi-bronchial anastomotic technique (A). We 
have learned from our experience with double lung transplantation that there are 
fewer airway complications with a bi-bronchial technique. Also, the bi-bronchial 
technique avoids dissection in the superior, middle, and posterior mediastinum. 
This significantly reduces the almost inevitable associated morbidity of bleeding 
from bronchial collateral structures in and around the carinal area. These 
collaterals are impressively enlarged in cyanotic patients, and their avoidance has 
been the key technical advantage that has simplified the procedure. Also, early in 
our experience we noted a small but appreciable risk of mycotic disruption of the 
aortic suture line when juxtaposed to the tracheal anastomosis. 
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10 (continued) The membranous portion of the airways is sewn first with continuous 
monofilament absorbable sutures while the cartilaginous portion is intussuscepted with an 
interrupted suture (B). (B reprinted with permission from Griffith BP, Magee MJ, 
Gonzalez IF, et al: Anastoinotic pitfalls in lung transplantation. J Thorac Cardiovasc Snrg 
107 :743-753,1994.) 
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1 1 The aortic anastomosis is completed at the mid-ascending level 
using a continuous running suture (A-B). Care must be taken to avoid 
too long a donor or recipient segment that might kink the aorta when 
joined. Also, it is common to be presented with a large recipient aortic 
circumference (ie, truncus arteriosus) that will require tailoring to fit 
the smaller donor vessel. If an atrial cuff technique is chosen, the right 
atrial anastomosis is completed next with a running suture (A). 
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11 (continued) It  is more common for us to perform the cardiac implantation 
with bicaval anastomoses (B). If a bicaval anastomosis is planned, then an ample 
amount of recipient cavae, which includes some atrium, must be left in place after 
excision of the recipient’s heart to provide a broad circumference for the 
anastomosis. 
With reperfusion of the heart, 500 mg of methylprednisolone is administered 
intravenously. Air in the left heart is vented from the dome of the ascending aorta 
and by an apically placed ventricular vent inserted via the left atrial appendage. As 
the patient is warmed from a core temperature of 28”C, a sinus rhythm usually 
begins spontaneously. Alternatively, pacing may be instituted. Partial bypass is 
achieved by releasing the caval tourniquets. The lungs are cautiously inflated and 
ventilated to remedy any lobar atelectasis. Each lung must be inspected for rotation 
or torsion of the individual lobes. Repeat bronchoscopy ensures that the bi- 
bronchial anastomoses are patent and the airways are clear of secretions. (1 to 9, 
1 0 A ,  and 11 are adapted and reprinted with permission from Griffith BP, et al: 
Cardiac and Cardiopulmonary Transplantation, in Starzl TR, Shapiro R, Simmons 
RL (eds): Organ Traiisplantation. Philadelphia, PA, Saunders, 1991 .) 
When the recipient is being weaned from cardiopulmo- 
nary bypass, an effort is made to minimize transfusions 
and, if necessary, inotropes are used to support the 
heart. Isoproterenol is avoided because of the common 
occurrence of bronchospasm. Positive end-expiratory 
pressure between S and 15 cni of water i.j useful, 
especially when pulmonary edema occLtrs as a result of 
a preservation injury. It is not uncommon to require 
peak airway pressures of up to 60 cm of water in order 
to oxygenate the patient, although an effort is made to 
maintain the lowest possible levels. The left and right 
chests are repeatedly inspected €or bleeding. When 
hemostasis is achieved, the pleural cavities and medias- 
tinum are drained. Initially, 36F tubes were placed to 
provide optimal dependent drainage from each chest. 
Air leaks along the large tracks of these chest tubes 
often occurred in asthenic recipients, and we now use 
32F tubes. The incision is closed in the usual manner, 
and the patient is readied for transport. 
When the patient arrives to the surgical intensive 
care unit, helshe is placed in an isolation room and 
cared for in the same manner as any other cardiac 
surgical patient. Vasoactive drugs and ventilatory sup- 
port are discontinued as soon as possible. Airway 
secretions containing blood and mucus are common, 
and endotracheal suctioning and bronchoscopy are 
performed routinely. It is our belief that it is far better 
to be aggressive about removing these secretions than to 
risk their impaction within the airways. 
DISCUSSION 
Combined heart and lung transplantation does not 
enjoy the success of isolated heart or single/double-lung 
transplantation. According to the most recently pub- 
lished ISHLT data, the 1-year survival rate for heart- 
lung transplant recipients is 60%, while the 11-year 
survival rate is 21'310.l' In comparison, 1-year survival 
after isolated heart and single-lung transplant is 79% 
and 75%, respectively. l1 
The ISHLT registry data offers insight into the 
decreased survival after heart-lung transplant. In the 
first 30 days postoperatively, death is primarily caused 
by graft failure and hemorrhage." From 30 days to 1 
year, postoperatively, the most common cause of death 
is infection." Our results at the University of Pitts- 
burgh documented a rate of infection in heart-lung 
transplant recipients of 3.0 infections per patient over 
an average follow-up of 9 months postoperatively. '* 
This rate is twice that seen in our heart-transplant 
recipients with a similar follow-up.'5 Bacterial isolates 
accounted for 50% of all infections. Sixty-four percent 
of patients also developed cytomegalovirus infection. 
The leading cause of death beyond 1 year after 
transplant is bronchiolitis obliterans. l1 Early reports 
cited obliterative bronchilitis in up to 50% of heart-lung 
transplants surviving beyond I year. '" A recent study 
from Papworth Hospital reported a rate of bronchialitis 
olditeraas of 28% and 55% of 126 patients analyzed at 2 
and 5 years posttransplant, respectively. '' In this re- 
port, the primary risk factor for developing bronchiol- 
itis ohliterans was the number of episodes of acute 
rejertion. 
The occurrence of acute rejection within the first 3 
months after heart-lung transplantation has heen iden- 
tified as an independent risk factor for death.18 Rejec- 
tion episodes typically involve the lung and occur 
without evidence of rejection on endomyocardial hi- 
opsy.19 For this reason. our protocol is to perform 
bronchoscopy with transbronchial biopsy and bronchio- 
alveolar lavage at least once during the first postopera- 
tive month. This is repeated at 2- to 3-month intervals 
or whenever rejection or infection is suspected." Endo- 
myocardial biopsy is not routinely performed. 
The triple-therapy oral immunosuppressive protocol 
at the University of Pittsburgh consists of: prednisone 
20 mglday; azathioprine 1.5 to 2.5 mglkglday; FK506 
(Fujisawa Corp, Japan) 0.2 to 0.3 mg/kg/day. It is our 
preference to use FK506 in place of cyclosporine based 
on our clinical trials in heart and lung transplant 
patients. These trials showed a lower incidence of acute 
rejection in heart transplant patients managed on 
FK506-based immunosuppression. Lung transplant re- 
cipients managed with FK506 had fewer episodes of 
bronchiolitis obliterans and a tendency toward fewer 
episodes of acute reje~tion.""~ 
In conclusion, heart-lung transplantation has made 
the transition from an experimental procedure to an 
accepted, successful therapy for a number of end-stage 
cardiopulmonary disorders. The surgical technique has 
evolved in such a way as to overcome the problems of 
airway dehiscence, hemorrhage, and nerve injury. 
Refinements in immunosuppression as well as the recog- 
nition and treatment of infection and rejection have 
resulted in long-term survival in these patients. With 
new UNOS strategies in allocation of organs and restric- 
tion of candidates to those with uncorrectable congeni- 
tal heart disease, the outlook for these deserving candi- 
dates may improve. 
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